PRINCETON, N.J.–(BUSINESS WIRE)–26 September 2024– Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride), an oral medication for the treatment of…Original Article
FDA Approves Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
